ISMIVS Newsletter March&April, 2023 Newsletter ISMIVS

ISMIVS Newsletter March&April, 2023

Newsletter 2023 Mar & Apr
2023年3&4月简报

About Us 国际微无创医学会简介

The International Society of Minimally Invasive and Virtual Surgery (ISMIVS, previously known as International Society of Minimally Invasive and Noninvasive Medicine) was founded in July 2013 at the gala of the 1st Yangtze International Summit of Minimally Invasive and Noninvasive Medicine in Chongqing, China. ISMIVS envisions to accelerating the progress in minimally invasive and noninvasive medicine by promoting research, education, communication, and international collaboration.
国际微无创医学会（ISMIVS）是在 2013 年 7 月在中国重庆召开的第一届国际微无创医学长江高峰论坛上宣布成立的，旨在通过学术研究、教育、交流以及国际合作加快微无创医学的发展。

Become a member 注册成为会员 >

The Personality in the Medical Education World 医学教育界的大人物

From the 2020 July issue of our ISMIVS Newsletter, we would like to introduce some pioneers in the field of minimally-invasive and noninvasive medicine. They are not only prestigious in their field but also willing to share their experience and ideas with younger doctors, hence making a great contribution to medical education. This issue features Prof. Mohamed Hamed, a leading expert in radiology from Egypt.

从 2020 年 7 月刊开始，国际微无创医学会将为大家介绍微无创医学领域的一些领军人物。他们不仅在各自的领域享负盛名，而且非常乐意与年轻医生分享他们的经验、理念和想法，从而为医学教育做出了巨大的贡献。本期月刊要介绍的是埃及的放射学专家Mohamed Hamed 教授。

Prof. Mohamed Hamed
MD
Assistant Professor of Radiology and Interventional Radiology at the University of Cairo
Mohamed Hamed教授
医学博士
开罗大学放射学和介入放射学副教授

Vice President of the International Society of Minimally Invasive and Virtual Surgery
Consultant Doctor of Cancer Intervention at the Affiliated Hospital, University of Cairo
Member of the European Interventional Radiology Association
国际微无创医学会副主席
开罗大学附属医院肿瘤介入治疗顾问医生
欧洲介入放射学协会会员

Prof. Mohamed Hamed is the Assistant Professor of Radiology and Interventional Radiology at the University of Cairo, and the Consultant Doctor of Cancer Intervention at the Affiliated Hospital, University of Cairo, he is also the Vice President of the International Society of Minimally Invasive and Virtual Surgery.
Mohamed Hamed教授是开罗大学放射学和介入放射学副教授，开罗大学附属医院肿瘤介入治疗顾问医生，也是国际微无创医学会副主席。
Prof. Hamed has supervised 14 different papers in different universities and has received various courses in Italy, Spain, Holland and China as well as sharing presentations in tens of conferences all over the world. He is currently having excellent experience in percutaneous tumour ablation techniques (RFA, MW, PEI, and IRE) in various organs. He has practised widely cancer pain and chronic degenerative pain intervention, as well as bone augmentation. Lately, he has been trained and licensed in HIFU technology treatment of solid tumours and gynaecological disorders. Prof. Hamed is the chairman of HIFU Egypt, the first private HIFU centre in the middle east and Africa practising HIFU non-invasive treatment of solid tumours.
Hamed教授指导了不同大学里面共14篇论文的写作，在意大利、西班牙、荷兰以及中国参加了多个课程的学习，并在数十个国际性的学术大会上作过学术报告。他尤其擅长于不同器官上的经皮肿瘤切除技术，包括射频消融（RFA）、微波消融（MW）、无水乙醇注射治疗（PEI）和纳米刀消融疗法（IRE），并有介入治疗癌性疼痛和慢性退行性疼痛以及骨增生的广泛经验。最近，Hamed教授经过培训获得了使用HIFU技术治疗实体肿瘤和妇科疾病的资质，此后，他负责组建了中东和非洲地区第一个私立的HIFU肿瘤治疗中心，目前是埃及海扶中心的负责人。
In addition, he is also an active member of many professional societies, such as the European Interventional Radiology Association, Arabian Society of Interventional Radiology, and Egyptian Society of Interventional Radiology, involved in numerous academic activities for the ongoing advancement in the field of interventional radiology.
此外，他也是欧洲介入放射学协会、阿拉伯介入放射学会和埃及介入放射学会等多个医学协会的活跃会员，积极参与学术活动，致力于推动介入放射领域的发展。

Watch his lecture on the management of liver tumour:

https://youtu.be/5GsIriJW05Y

观看Hamed教授关于肝肿瘤治疗的讲课视频：

https://youtu.be/5GsIriJW05Y

News 新闻

Embrace Uterus Health: the World's 4th Multicenter Telemedicine Womb-Preserving Campaign Celebrates International Women's Day
第四届全球多中心远程协同手术保子宫公益行动成功举办

Led by the International Society of Minimally Invasive and Virtual Surgery (ISMIVS) and Chongqing Charity Federation (CQCF), the State Key Laboratory of Ultrasound in Medicine and Engineering (SKLUME) and National Engineering Research Center of Ultrasound Medicine in China (NERCUM) organized the World's 4th Multicenter Telemedicine Womb-Preserving Campaign (hereinafter referred to as "the Campaign") on March 7 in Liangjiang New Area, Chongqing China, together with 185 HIFU Centers worldwide. Themed Embrace Uterus Health, the Campaign aims to help women suffering from uterine problems with high-intensity focused ultrasound (HIFU), a noninvasive technology originally born in China, in a nonprofit way.
3 月 7 日，在国际微无创医学会、重庆市慈善总会指导下，由超声医学工程国家重点实验室、超声医疗国家工程研究中心联合全球 185 家医院海扶®微无创治疗中心，在重庆两江新区举办了第四届全球多中心远程协同手术保子宫公益行动（以下简称“公益活动”）。本次公益活动主题为“久久卫宫，与爱同行”，旨在通过免费帮扶、减免费用等形式，用中国原创的无创聚焦超声消融技术为全球女性解决子宫疾病困扰。
On this major occasion, NERCUM, SKLUME and CQCF jointly launched a financial assistance program to protect reproductive health. In addition, the Campaign reflected on the achievements of medical staff who have worked hard in public education of HIFU treatment by granting the SKLUME award of “Annual HIFU Influencers of 2022”.
现场，超声医疗国家工程研究中心、超声医学工程国家重点实验室携手重庆市慈善总会，共同启动“久久卫宫”公益项目。同时，对 2022 年度微无创领域科普宣传表现突出的医护人员，由超声医学工程国家重点实验室对其授予“2022 年度聚焦超声领域科普达人”称号，并给予表彰。
Prof. Wang Zhibiao, Director of SKLUME and NERCUM, addressed on behalf of the organizing committee that HIFU was a technology for all human beings and could treat diseases and, more importantly, preserve organs. A doctor shall offer both super medical skills and a great love embodied by minimally invasive and noninvasive philosophy, so as to minimize the harm to the ill.
超声医学工程国家重点实验室、超声医疗国家工程研究中心主任王智彪代表主办方致辞。王智彪表示，焦超声消融技术是属于全人类的技术，不仅能治疗疾病，更重要的是保器官，医生不仅需要掌握高端的技术，还要有微无创的思想，使用对人体伤害更小的方法治疗病患。
Prof. David Cranston, Associate Professor of Surgery in the Nuffield Department of Surgical Sciences at the University of Oxford and President of ISMIVS, delivered an opening speech virtually. He indicated that based on the data collected in ISMIVS 2022 Annual Report, the treatment number of 270 HIFU Centers, until the end of the Year 2022, 246821 cases of solid tumours have been treated since 2010, among which 70-80% are fibroids, demonstrating the significant role HIFU therapy has played in improving women’s health.
英国牛津大学教授、国际微无创医学会主席 David Cranston 通过线上致辞，他表示，根据国际微无创医学会收集的全球 270 家海扶中心治疗数据，2010-2022 年总治疗量中子宫肌瘤占比 70-80%，聚焦超声消融技术为促进全球女性子宫健康做出了杰出贡献。
Prof. Lang Jinghe, academician of the Chinese Academy of Engineering (CAE) and honorary professor of Gynecology and Obstetrics in PUMC Hospital, wrote an inscription for this Campaign – Caring for Women and Protecting Uterus. In his speech, Prof. Lang said that the standard of surgery should not be its scope or complexity, on the contrary, less surgical or even nonsurgical approach should be the goal we all pursue. HIFU therapy has become a shining greeting card to the world of China-made, China brands, China technologies and China guidelines.
中国工程院院士、北京协和医院妇产科名誉主任郎景和教授为本次公益活动题字：关爱妇女保护子宫公益活动。在致辞时，郎景和院士表示，外科手术不是越大、越复杂越好，而是少做手术，甚至不做手术。无创伤的聚焦超声消融手术已经成为了一张名片，向全世界展示了中国制造、中国品牌、中国技术、中国指南。
On the same day, 185 global HIFU Centers performed HIFU treatment simultaneously on live, breaking the regional barriers. Prof. Zhang Lian, Prof. Yang Wuwei, Prof. Mohamed Hamed, Dr Wang Qiulin and other experts in the field of minimally invasive and non-invasive medicine participated in the discussion of a typical case that was conducted at Mahkota Medical Center, Malaysia. They put forward treatment suggestions and monitored the operation progress in real-time through the Global Telemedicine Center for HIFU Therapy.
当日，全球 185 家医院的海扶®微无创治疗中心进行跨区域同步手术直播。微无创领域专家张炼、杨武威、Hamed教授、王秋麟等人对马来西亚仁爱医院的典型病例进行分析并提出治疗建议，并通过聚焦超声消融手术全球协同服务中心实时监控手术进展。

Case Studies 病例分享

While there are clear limitations to the methodology of case studies in the determination of treatment protocol and establishment of new trials, the observation of a single patient can add to our understanding of aetiology, pathogenesis, natural history, treatment option and complications to promote the medical development of a particular disease, and to the clinical practice of potential junior investigators.
尽管病例研究方法在确定治疗方案、组织新的临床试验方面存在明显局限性，但对单个病例的观察研究可以帮助我们了解病因、发病机制、自然病程、治疗方法及并发症，从而促进特定疾病的医学发展，并助益初级研究人员的临床实践。
TThe case below was shared by Prof. He Min at the 2022 APAGE-OGSM-ISMIVS Conference of Minimally Invasive and Noninvasive Surgery (Malaysia)
本期病例由何敏教授于 2022 年 APAGE-OGSM-ISMIVS 微无创治疗联合会议上分享。

Patient Info 患者信息
78 years old patient with pancreatic cancer
Could not tolerate surgery and chemotherapy
CA199 was 426.5U/ml before treatment
After HIFU treatment, the volume decreased by 64.4%(26.9U/ml) in 3 months, 79.9%(324U/ml) in 6 months, and 81%(984, 3U/ml) in 15months
78岁胰腺癌患者
无法承受手术和化疗
接受HIFU治疗前CA199为 426.5U/ml
HIFU治疗后3个月内CA199下降64.4%(26.9U/ml)
6个月后下降79.9%(324U/ml)
15个月后下降81%(984, 3U/ml)

Watch the Lecture >

HIFU Special Issue 高强度聚焦超声特刊

We are delighted to announce that the International Journal of Hyperthermia, the HIFU Special Issue (i.e. Volume 38, 2021), which was partially supported by ISMIVS, was officially released in September. The Special Issue includes 15 articles written and reviewed by world-renowned scholars and pioneers in minimally invasive and noninvasive medicine, elaborating on the status and prospects of the clinical applications of high intensity focused ultrasound on tumours that occurred in specific organs. We'll share the 15 articles included in the upcoming newsletters, stay tuned!
我们很高兴地向大家宣布，由国际微无创医学会（ISMIVS）参与并大力支持的《国际热疗杂志：高强度聚焦超声（HIFU）特刊》已于九月正式发布。本期特刊邀请到多位微无创医学领域的国际知名专家和行业先驱参与编撰及审核，共包含15篇学术文章，阐述了高强度聚焦超声（HIFU）治疗人体各器官肿瘤的临床应用现状和发展前景。我们将陆续分享HIFU特刊中的文章，敬请期待！

Effectiveness of focused ultrasound for high-risk human papillomavirus infection-related cervical lesions
聚焦超声对高危人乳头瘤病毒感染相关宫颈病变的疗效

A retrospective cohort study was performed from January 2017 to December 2019. A total of 592 patients were enrolled, of which 300 patients were treated with FU and 292 patients were treated with interferon drugs.
2017 年 1 月至 2019 年 12 月进行回顾性队列研究，共纳入 592 例患者，其中300例接受聚焦超声(FU)治疗，292 例接受干扰素类药物治疗。
The median time for HR-HPV clearance was 6.00 months (95% CI: 5.24-6.76) in the FU group and 26.00 months (95% CI: 22.32-29.68) in the medication group. A significant difference was observed between the two groups (χ2 =198.902, p = 0.000). The HR-HPV clearance rate was 4.927 (95% CI 3.840-6.321; p = 0.000) times higher in the patients treated with FU than those treated with interferon drugs.
FU 组 HR-HPV 清除的中位时间为 6.00 个月（95% CI：5.24-6.76），药物组为 26.00 个月（95% CI：22.32-29.68）。两组之间存在显着差异 (χ2 =198.902, p = 0.000)。接受 FU 治疗的患者的 HR-HPV 清除率比接受干扰素药物治疗的患者高 4.927（95% CI 3.840-6.321；p = 0.000）倍。
FU therapy can eliminate HR-HPV infections in a short period of time. Moreover, the treatment efficacy of FU was significantly superior to that of interferon drugs.
FU 疗法可以在短时间内消除HR-HPV感染。而且，FU 的治疗效果明显优于干扰素类药物。